
  
    
      
        Background_NNP
        In_IN spite_NN of_IN advances_NNS in_IN surgical_JJ and_CC pharmacological_JJ
        treatment_NN ,_, about_IN half_NN of_IN the_DT aneurysmal_NN subarachnoid_NN
        hemorrhage_NN (_( SAH_NNP )_) patients_NNS die_VBP and_CC many_JJ who_WP survive_VBP need_VBP
        rehabilitation_NN to_TO maintain_VB independence_NN ,_, causing_VBG
        significant_JJ economic_JJ losses_NNS to_TO medical_JJ and_CC social_JJ care_NN ._.
        About_IN 90_CD %_NN of_IN SAH_NNP cases_NNS are_VBP caused_VBN by_IN a_DT ruptured_VBN IA_NNP [_NN 1_CD ]_NN ._.
        Per-case_NNP mortality_NN for_IN ruptured_VBD IAs_NNP is_VBZ about_IN 30_CD to_TO 50_CD %_NN and_CC
        morbidity_NN about_IN 66_CD %_NN as_IN opposed_VBN to_TO about_IN 2_CD %_NN mortality_NN and_CC 4_CD %_NN
        morbidity_NN for_IN elective_JJ surgery_NN of_IN unruptured_JJ IAs_NNP in_IN
        asymptomatic_JJ low-risk_JJ patients_NNS [_NN 2_CD 3_CD ]_NN ._. Given_VBN the_DT marked_VBN
        contrast_NN between_IN the_DT outcomes_NNS of_IN elective_JJ versus_CC emergency_NN
        surgery_NN ,_, the_DT goal_NN has_VBZ to_TO be_VB identification_NN and_CC treatment_NN of_IN
        IAs_NNP prior_RB to_TO rupture_NN ._.
        There_EX is_VBZ substantial_JJ debate_NN regarding_VBG the_DT cost-benefit_JJ
        ratio_NN of_IN population_NN screening_NN [_NN 4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ._. Restricting_NNP
        screening_NN to_TO those_DT individuals_NNS at_IN high_JJ risk_NN both_DT for_IN
        developing_VBG IA_NNP and_CC for_IN rupture_NN would_MD improve_VB the_DT
        cost-benefit_JJ ratio_NN ._. Characterization_NNP of_IN environmental_JJ and_CC
        genetic_JJ risk_NN factors_NNS would_MD allow_VB not_RB only_RB reduction_NN of_IN risk_NN
        through_IN behavior_NN modification_NN ,_, but_CC also_RB significantly_RB
        improve_VB detection_NN ._. Additionally_RB ,_, some_DT environmental_JJ and_CC
        genetic_JJ risk_NN factors_NNS may_MD be_VB amenable_JJ to_TO pharmacological_JJ
        intervention_NN ._. Simple_NN tests_NNS for_IN genetic_JJ risk_NN factors_NNS would_MD
        permit_VB the_DT identification_NN of_IN individuals_NNS at_IN high_JJ risk_NN for_IN
        development_NN and_CC rupture_NN of_IN aneurysms_NNS ,_, consequently_RB allowing_VBG
        diagnostic_JJ effort_NN to_TO be_VB concentrated_VBN on_IN a_DT smaller_JJR group_NN
        that_WDT is_VBZ at_IN higher_JJR risk_NN ._.
        Currently_RB ,_, several_JJ risk_NN factors_NNS have_VBP been_VBN identified_VBN
        including_VBG cigarette_NN smoking_NN ,_, arterial_NN hypertension_NN ,_, gender_NN ,_,
        aging_VBG ,_, atherosclerosis_NNS and_CC heavy_JJ alcohol_NN consumption_NN [_NN 9_CD 10_CD
        11_CD 12_CD ]_NN ._. Initial_JJ indications_NNS of_IN a_DT genetic_JJ component_NN were_VBD
        based_VBN on_IN collections_NNS of_IN case_NN reports_NNS that_WDT suggested_VBD that_IN
        IAs_NNP are_VBP associated_VBN with_IN some_DT rare_JJ simple_JJ Mendelian_NNP
        disorders_NNS ,_, e_SYM ._. g_SYM ._. autosomal_NN dominant_JJ polycystic_JJ kidney_NN
        disease_NN ,_, Ehlers_NNP Danlos_NNP syndrome_NN type_NN IV_NNP and_CC the_DT Marfan_NNP
        syndrome_NN [_NN 13_CD ]_NN ._. More_RBR recent_JJ systematic_JJ prevalence_NN
        estimates_NNS indicate_VBP either_CC absence_NN of_IN association_NN or_CC
        markedly_RB reduced_VBN prevalence_NN of_IN IA_NNP among_IN patients_NNS with_IN rare_JJ
        simple_JJ Mendelian_NNP disorders_NNS [_NN 14_CD 15_CD ]_NN ._. Also_RB ,_, genetic_JJ
        analyses_NNS of_IN genes_NNS known_VBN to_TO cause_VB some_DT simple_JJ Mendelian_NNP
        disorders_NNS have_VBP proven_VBN negative_JJ for_IN collections_NNS of_IN patients_NNS
        with_IN IA_NNP [_NN 16_CD 17_CD ]_NN ._. The_DT familial_NN occurrence_NN of_IN IAs_NNP not_RB
        associated_VBN with_IN known_VBN simple_JJ Mendelian_NNP disorders_NNS was_VBD first_RB
        noted_VBD in_IN 1942_CD [_NN 18_CD ]_NN and_CC ,_, since_IN then_RB ,_, nearly_RB one_CD hundred_CD
        case_NN reports_NNS and_CC review_NN articles_NNS have_VBP been_VBN published_VBN ._.
        Population-based_NNP studies_NNS of_IN SAH_NNP probands_NNS show_VBP that_IN 7_CD to_TO 10_CD %_NN
        have_VBP a_DT family_NN history_NN of_IN IA_NNP ,_, a_DT higher_JJR percentage_NN than_IN
        previously_RB appreciated_VBN [_NN 1_CD 19_CD 20_CD ]_NN ._. These_DT familial_NN IA_NNP
        (_( FIA_NNP )_) families_NNS have_VBP no_DT signs_NNS of_IN any_DT other_JJ simple_JJ Mendelian_NNP
        disorders_NNS predisposing_VBG to_TO IA_NNP ,_, supporting_VBG the_DT possibility_NN
        that_IN some_DT or_CC all_DT IAs_NNP have_VBP a_DT genetic_JJ component_NN ,_, and_CC that_IN FIA_NNP
        is_VBZ a_DT genetic_JJ disease_NN separate_JJ and_CC apart_RB from_IN previously_RB
        defined_VBN diseases_NNS ._. The_DT inheritance_NN patterns_NNS of_IN FIA_NNP have_VBP not_RB
        been_VBN determined_VBN ,_, partly_RB because_IN IA_NNP is_VBZ a_DT late_JJ age-at-onset_JJ
        disease_NN and_CC partly_RB because_IN it_PRP is_VBZ likely_JJ to_TO be_VB a_DT
        multifactorial_NN disease_NN for_IN which_WDT simple_JJ Mendelian_NNP models_NNS
        will_MD not_RB fit_VB well_RB [_NN 1_CD 21_CD 22_CD 23_CD ]_NN ._.
      
      
        Methods_NNP
        
          Study_NN subjects_NNS
          Eighty-five_CD families_NNS with_IN at_IN least_JJS two_CD members_NNS with_IN
          ruptured_VBD or_CC unruptured_JJ IA_NNP and_CC no_DT family_NN history_NN of_IN
          polycystic_JJ kidney_NN disease_NN were_VBD ascertained_JJ from_IN a_DT
          sampling_VBG frame_NN of_IN 1150_CD consecutive_JJ patients_NNS treated_VBN
          between_IN 1977_CD and_CC 1990_CD for_IN aneurysmal_NN SAH_NNP by_IN the_DT
          Department_NNP of_IN Neurosurgery_NNP at_IN the_DT University_NNP Hospital_NNP of_IN
          Kuopio_NNP ,_, which_WDT serves_VBZ a_DT genetically_RB homogenous_JJ population_NN
          of_IN 870_CD ,_, 000_CD in_IN eastern_JJ Finland_NNP [_NN 1_CD ]_NN ._. Initially_RB ,_, family_NN
          history_NN was_VBD assessed_VBN by_IN a_DT short_JJ questionnaire_NN and_CC all_DT
          putative_JJ cases_NNS were_VBD confirmed_VBN from_IN medical_JJ and_CC autopsy_NN
          records_NNS ._. Due_JJ to_TO the_DT high_JJ mortality_NN of_IN IA_NNP and_CC lack_NN of_IN
          pre-rupture_JJ symptoms_NNS ,_, surviving_VBG relatives_NNS with_IN known_VBN IA_NNP
          were_VBD rare_JJ ._. We_PRP therefore_RB used_VBD magnetic_JJ resonance_NN
          angiography_NN to_TO screen_VB 264_CD siblings_NNS over_IN the_DT age_NN of_IN 30_CD of_IN
          the_DT IA_NNP probands_NNS [_NN 1_CD ]_NN ._. Positive_JJ magnetic_JJ resonance_NN
          angiography_NN findings_NNS were_VBD then_RB confirmed_VBN using_VBG digital_JJ
          subtraction_NN angiography_NN ._. Upper-abdominal_NNP ultrasonography_NN
          was_VBD performed_VBN on_IN all_DT screened_VBD individuals_NNS and_CC confirmed_VBD
          that_DT none_NN of_IN these_DT individuals_NNS had_VBD evidence_NN of_IN polycystic_JJ
          kidney_NN disease_NN ._. In_IN this_DT manner_NN ,_, we_PRP detected_VBD 30_CD siblings_NNS
          with_IN asymptomatic_JJ IA_NNP ,_, giving_VBG a_DT total_NN of_IN 49_CD affected_VBN sib_NN
          pairs_NNS from_IN 25_CD sibships_NNS (_( 22_CD extended_VBN families_NNS ;_: families_NNS
          10_CD ,_, 21_CD and_CC 29_CD had_VBD two_CD sibships_NNS each_DT ;_: Figure_NN 1_CD and_CC Table_NNP
          1_LS )_) ._. One_CD non-sib_JJ pair_NN was_VBD detected_VBN in_IN one_CD of_IN the_DT sibships_NNS
          in_IN family_NN 21_CD (_( see_VB Statistical_NNP analyses_NNS below_IN ;_: Figure_NN 1_LS )_)
          and_CC eliminated_VBN from_IN the_DT analyses_NNS ,_, leaving_VBG 48_CD ASPs_NNP for_IN the_DT
          genome_NN scan_VB ._. The_DT ASPs_NNP were_VBD comprised_VBN of_IN 26_CD males_NNS and_CC 34_CD
          females_NNS ._. Blood_NNP samples_NNS were_VBD obtained_VBN from_IN affected_VBN family_NN
          members_NNS ,_, unaffected_JJ siblings_NNS ,_, and_CC parents_NNS ,_, where_WRB
          possible_JJ ._. Due_JJ to_TO the_DT late_JJ age_NN at_IN onset_NN ,_, parents_NNS were_VBD
          available_JJ in_IN only_RB a_DT few_JJ of_IN the_DT families_NNS ._. All_DT family_NN
          records_NNS were_VBD confirmed_VBN through_IN registries_NNS kept_VBN by_IN the_DT
          Evangelical_NNP Lutheran_NNP Church_NNP of_IN Finland_NNP ._.
          The_DT study_NN protocol_NN was_VBD reviewed_VBN and_CC approved_VBN by_IN the_DT
          Institutional_NNP Review_NNP Boards_NNP of_IN both_DT the_DT University_NNP
          Hospital_NNP of_IN Kuopio_NNP and_CC Wayne_NNP State_NNP University_NNP ._.
        
        
          Study_NN design_NN
          Whole-genome_NNP scans_NNS are_VBP labor-intensive_JJ and_CC costly_JJ
          since_IN each_DT individual_NN in_IN the_DT study_NN must_MD be_VB genotyped_JJ for_IN
          all_DT markers_NNS ._. Reduction_NNP of_IN the_DT number_NN of_IN samples_NNS
          genotyped_JJ ,_, or_CC the_DT number_NN of_IN markers_NNS ,_, or_CC both_DT ,_, has_VBZ been_VBN
          shown_VBN to_TO be_VB efficient_JJ [_NN 24_CD 25_CD 26_CD 27_CD 28_CD ]_NN ._. We_PRP used_VBD a_DT
          two-stage_JJ design_NN ._. In_IN stage_NN 1_CD ,_, samples_NNS are_VBP genotyped_JJ at_IN
          low_JJ density_NN and_CC subsequently_RB at_IN higher_JJR density_NN in_IN stage_NN
          2_CD ,_, thereby_RB reducing_VBG the_DT overall_JJ number_NN of_IN markers_NNS
          genotyped_JJ ._. Stage_NN 1_CD data_NNS were_VBD analysed_JJ using_VBG a_DT liberal_JJ α_NN ≈_NN
          0_CD ._. 05_CD (_( lod_NN =_SYM 0_CD ._. 8_CD )_) ._. Regions_NNP exceeding_VBG the_DT threshold_NN were_VBD
          genotyped_JJ in_IN stage_NN 2_CD ._.
          Power_NNP was_VBD computed_JJ assuming_VBG a_DT two-stage_JJ design_NN ,_, 49_CD
          ASPs_NNP ,_, and_CC a_DT map_NN density_NN of_IN 15_CD cM_NN ._. For_IN stage_NN I_PRP alone_RB ,_, we_PRP
          had_VBD at_IN least_JJS 96_CD %_NN power_NN to_TO detect_VB "_'' significant_JJ linkage_NN "_''
          (_( lod_NN score_NN of_IN 3_CD ._. 6_CD )_) [_NN 29_CD ]_NN to_TO a_DT locus_JJ with_IN a_DT
          locus-specific_JJ relative_JJ risk_NN to_TO siblings_NNS of_IN 8_CD and_CC at_IN
          least_JJS 90_CD %_NN power_NN to_TO detect_VB "_'' suggestive_JJ linkage_NN "_'' to_TO a_DT locus_JJ
          with_IN a_DT locus-specific_JJ relative_JJ risk_NN of_IN 4_CD ._.
        
        
          DNA_NN isolation_NN and_CC pre-amplification_JJ
          Blood_NNP was_VBD collected_VBN into_IN EDTA-containing_NNP tubes_NNS ._.
          Genomic_NNP DNA_NNP was_VBD isolated_VBN either_CC by_IN an_DT automated_VBN procedure_NN
          (_( Genepure_NNP DNA_NNP extractor_NN ,_, Applied_NNP Biosystems_NNP ,_, Inc_NNP ._. ,_, Foster_NNP
          City_NNP ,_, CA_NNP )_) or_CC manually_RB (_( Puregene_NNP DNA_NNP isolation_NN kit_NN ,_, Gentra_NNP
          Systems_NNPS ,_, Inc_NNP ._. ,_, Minneapolis_NNP ,_, MN_NNP )_) ._. Genotyping_NNP was_VBD performed_VBN
          using_VBG genomic_JJ DNA_NNP ,_, either_CC untreated_JJ or_CC amplified_VBN linearly_RB
          using_VBG primer-extension_JJ preamplification_NN [_NN 30_CD 31_CD ]_NN ._.
          Approximately_RB 0_CD ._. 5_CD μg_NN genomic_JJ DNA_NNP was_VBD used_VBN for_IN
          preamplification_NN with_IN an_DT N_NNP 
          15_CD -_: primer_NN [_NN 30_CD 31_CD ]_NN ._. The_DT resulting_VBG
          preamplified_JJ DNA_NNP was_VBD then_RB used_VBN as_IN a_DT template_NN in_IN marker_NN
          PCRs_NNP with_IN specific_JJ primers_NNS ._.
        
        
          Genotyping_NNP
          Most_JJS of_IN the_DT initial_JJ genotyping_VBG was_VBD performed_VBN by_IN the_DT
          National_NNP Heart_NNP Lung_NNP and_CC Blood_NNP Institute_NNP Mammalian_NNP
          Genotyping_NNP Service_NNP at_IN the_DT Marshfield_NNP Research_NNP Foundation_NNP
          using_VBG the_DT 10_CD cM_NN Weber_NNP version_NN 8_CD screening_NN set_VBD [_NN 32_CD ]_NN ._.
          Primer_NNP pairs_NNS for_IN additional_JJ markers_NNS were_VBD obtained_VBN from_IN
          Research_NNP Genetics_NNP ,_, Inc_NNP ._. (_( Huntsville_NNP ,_, AL_NNP )_) ._. For_IN the_DT
          additional_JJ genotyping_VBG ,_, PCRs_NNP were_VBD carried_VBN out_IN with_IN one_CD of_IN
          the_DT primers_NNS radioactively_RB labeled_VBN ._. PCRs_NNP were_VBD set_VBN up_RP using_VBG
          a_DT laboratory_NN workstation_NN (_( Biomek_NNP 1000_CD ;_: Beckman_NNP ,_, Palo_NNP
          Alto_NNP ,_, CA_NNP )_) and_CC performed_VBN in_IN PEC_NNP 9600_CD thermal_JJ cyclers_NNS
          (_( Perkin_NNP Elmer_NNP Cetus_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) ._. The_DT alleles_NNS were_VBD
          scored_VBN visually_RB from_IN autoradiographs_NNS and_CC entered_VBD into_IN an_DT
          Oracle_NNP database_NN (_( Oracle_NNP Corp_NNP ._. ,_, Redwood_NNP Shores_NNP ,_, CA_NNP )_) ._.
          Population_NN frequencies_NNS for_IN each_DT marker_NN were_VBD estimated_VBN
          from_IN a_DT sample_NN of_IN 20_CD to_TO 24_CD unrelated_JJ Finnish_JJ subjects_NNS ._.
        
        
          Statistical_NNP analyses_NNS
          A_DT Markov-process-based_NNP test_NN of_IN genetic_JJ relationship_NN [_NN
          33_CD ]_NN using_VBG all_PDT the_DT marker_NN data_NN across_IN the_DT genome_NN was_VBD used_VBN
          on_IN each_DT nuclear_JJ family_NN to_TO confirm_VB the_DT sib-pair_JJ
          relationship_NN ;_: one_CD non-sib_JJ pair_NN was_VBD detected_VBN in_IN one_CD of_IN the_DT
          sibships_NNS in_IN family_NN 21_CD (_( Figure_NN ._. 1_LS )_) and_CC eliminated_VBN from_IN the_DT
          analyses_NNS ._. The_DT results_NNS were_VBD consequently_RB derived_VBN from_IN 24_CD
          sibships_NNS (_( Figure_NN 1_LS )_) ._.
          The_DT genotype_NN data_NN were_VBD analyzed_VBN for_IN genetic_JJ linkage_NN
          with_IN both_DT single-marker_JJ and_CC multipoint_NN model-free_JJ ASP_NNP lod_NN
          score_NN analysis_NN [_NN 34_CD ]_NN using_VBG the_DT computer_NN program_NN
          MAPMAKER_NNP /_NN SIBS_NNP [_NN 35_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Genome-wide_NNP linkage_NN analysis_NN
          We_PRP performed_VBD stage_NN I_PRP of_IN a_DT two-stage_JJ genome_NN scan_VB using_VBG
          the_DT 48_CD Finnish_JJ ASPs_NNP ._. Due_JJ to_TO the_DT genetic_JJ homogeneity_NN of_IN
          the_DT Finnish_JJ population_NN [_NN 36_CD 37_CD 38_CD 39_CD 40_CD ]_NN the_DT probability_NN
          of_IN identifying_VBG genetic_JJ risk_NN factors_NNS in_IN a_DT complex_JJ disease_NN
          such_JJ as_IN FIA_NNP may_MD be_VB substantially_RB improved_VBN [_NN 37_CD 38_CD 40_CD ]_NN ._.
          In_IN the_DT first_JJ stage_NN a_DT 10_CD cM_NN genome_NN scan_VB was_VBD performed_VBN
          using_VBG the_DT Weber_NNP screening_NN set_VBD 8_CD [_NN 32_CD ]_NN and_CC the_DT data_NNS
          analyzed_VBD using_VBG both_DT two-point_JJ and_CC multipoint_NN ASP_NNP linkage_NN
          analysis_NN ._. Seven_CD regions_NNS on_IN chromosomes_NNS 4_CD ,_, 6_CD ,_, 7_CD p_NN ,_, 7_CD q_NN ,_, 14_CD ,_,
          19_CD ,_, and_CC X_NNP ,_, with_IN multipoint_NN lod_NN scores_NNS exceeding_VBG 0_CD ._. 8_CD
          (_( pointwise_NN P-_NNP value_NN ≈_NN 0_CD ._. 05_CD )_) were_VBD identified_VBN (_( Table_NNP 2_LS )_) ._. Two_CD
          regions_NNS had_VBD MLSs_NNP exceeding_VBG 2_CD ._. 0_CD (_( 2_CD ._. 58_CD on_IN chromosome_NN 19_CD ;_:
          2_CD ._. 08_CD on_IN chromosome_NN X_NNP )_) ._. Two-point_NNP lod_NN scores_NNS exceeded_VBD 1_CD ._. 0_CD
          for_IN two_CD adjacent_JJ markers_NNS in_IN each_DT of_IN these_DT regions_NNS ,_, ruling_NN
          out_IN substantial_JJ genotyping_VBG error_NN in_IN one_CD marker_NN as_IN the_DT
          cause_NN of_IN the_DT high_JJ lod_NN scores_NNS ._. Three_CD additional_JJ regions_NNS
          with_IN multipoint_NN lod_NN scores_NNS exceeding_VBG 0_CD ._. 8_CD (_( chromosomes_NNS 4_CD ,_,
          6_CD ,_, and_CC 7_CD q_NN )_) also_RB had_VBD substantial_JJ two-point_JJ lod_NN scores_NNS at_IN
          more_JJR than_IN one_CD marker_NN ._. For_IN two_CD regions_NNS (_( 7_CD p_NN and_CC 14_CD q_NN )_) ,_,
          however_RB ,_, only_RB one_CD marker_NN had_VBD a_DT high_JJ two-point_JJ lod_NN score_NN ._.
          In_IN both_DT cases_NNS ,_, the_DT significant_JJ marker_NN was_VBD either_CC the_DT
          first_JJ or_CC the_DT last_JJ marker_NN typed_VBN on_IN the_DT chromosome_NN ._.
          Following_VBG conventional_JJ guidelines_NNS ,_, we_PRP considered_VBD an_DT MLS_NNP
          of_IN 3_CD ._. 6_CD or_CC greater_JJR to_TO be_VB "_'' significant_JJ linkage_NN "_'' and_CC an_DT MLS_NNP
          of_IN 2_CD ._. 2_CD to_TO be_VB "_'' suggestive_JJ linkage_NN "_'' [_NN 29_CD ]_NN ._.
          In_IN stage_NN 2_CD ,_, we_PRP genotyped_JJ additional_JJ markers_NNS in_IN the_DT
          seven_CD regions_NNS identified_VBN in_IN stage_NN 1_CD ._. Four_CD additional_JJ
          markers_NNS flanking_VBG D_NNP 7_CD S_NNP 1819_CD on_IN 7_CD p_NN and_CC nine_CD additional_JJ
          markers_NNS flanking_VBG D_NNP 14_CD S_NNP 1434_CD on_IN 14_CD q_NN were_VBD typed_VBN and_CC the_DT
          resulting_VBG maximum_NN MLSs_NNP were_VBD 0_CD ._. 28_CD (_( 7_CD p_NN )_) and_CC 0_CD ._. 80_CD (_( 14_CD q_NN )_) ,_,
          indicating_VBG that_IN the_DT previous_JJ linkage_NN signals_NNS were_VBD likely_JJ
          due_NN to_TO the_DT increased_VBN statistical_JJ variability_NN commonly_RB
          seen_VBN in_IN the_DT multipoint_NN signal_NN at_IN the_DT most_RBS extreme_JJ
          markers_NNS ._. We_PRP therefore_RB eliminated_VBD regions_NNS 7_CD p_NN and_CC 14_CD q_NN from_IN
          further_JJ consideration_NN ._. Additional_JJ markers_NNS were_VBD typed_VBN in_IN
          the_DT two_CD regions_NNS on_IN chromosome_NN 19_CD and_CC X_NNP with_IN maximum_NN MLSs_NNP
          exceeding_VBG 2_CD ._. 0_CD ._. A_DT multipoint_NN plot_NN for_IN the_DT chromosome_NN 19_CD is_VBZ
          shown_VBN in_IN Figure_NN 2_CD ;_: the_DT maximum_JJ MLS_NNP was_VBD 2_CD ._. 58_CD at_IN D_NNP 19_CD S_NNP 245_CD -_:
          D_NNP 19_CD S_NNP 246_CD ._. The_DT maximum_JJ MLS_NNP for_IN chromosome_NN X_NNP decreased_VBD from_IN
          2_CD ._. 08_CD at_IN DXS_NNP 987_CD to_TO 1_CD ._. 33_CD at_IN DXS_NNP 1226_CD ,_, (_( about_IN 10_CD cM_NN
          centromeric_JJ from_IN DXS_NNP 987_CD )_) ._. The_DT MLS_NNP for_IN the_DT region_NN on_IN
          chromosome_NN X_NNP decreased_VBD considerably_RB with_IN the_DT addition_NN of_IN
          several_JJ new_JJ markers_NNS and_CC consequent_JJ improvement_NN in_IN the_DT
          accuracy_NN of_IN the_DT multipoint_NN allele-sharing_JJ estimates_NNS ,_,
          which_WDT were_VBD clearly_RB overestimated_JJ when_WRB only_RB the_DT initial_JJ
          scan_VB markers_NNS were_VBD included_VBN in_IN the_DT analysis_NN ._. All_DT the_DT
          evidence_NN for_IN linkage_NN in_IN this_DT region_NN was_VBD due_JJ to_TO 8_CD
          brother-brother_JJ pairs_NNS ;_: the_DT 16_CD sister-sister_JJ pairs_NNS and_CC the_DT
          25_CD brother-sister_JJ pairs_NNS gave_VBD maximum_NN MLSs_NNP close_VBP to_TO zero_CD
          in_IN this_DT region_NN ._.
        
      
      
        Discussion_NNP
        The_DT relatively_RB high_JJ prevalence_NN of_IN IAs_NNP and_CC aneurysmal_NN SAH_NNP
        place_NN the_DT disease_NN in_IN the_DT group_NN of_IN moderately_RB common_JJ
        disorders_NNS ._. Consequently_RB ,_, it_PRP shares_VBZ some_DT of_IN the_DT features_NNS
        that_WDT make_VBP common_JJ disorders_NNS complex_JJ with_IN respect_NN to_TO genetic_JJ
        analysis_NN ._. These_DT include_VBP :_: low_JJ sibling_VBG relative_JJ risks_NNS due_JJ to_TO
        the_DT high_JJ population_NN prevalence_NN ;_: presence_NN of_IN multiple_JJ
        genetic_JJ loci_NN ,_, each_DT contributing_VBG a_DT small_JJ portion_NN of_IN the_DT
        sibling_VBG relative_JJ risk_NN ;_: incomplete_JJ penetrance_NN of_IN genetic_JJ
        loci_NN ;_: environmental_JJ risk_NN factors_NNS ;_: late_JJ age_NN at_IN onset_NN ;_: and_CC
        phenocopies_NNS ,_, i_NNP ._. e_SYM ._. disease_NN due_JJ to_TO purely_RB environmental_JJ
        factors_NNS ._. Additional_JJ complexity_NN for_IN genetic_JJ analysis_NN arises_VBZ
        due_JJ to_TO diagnostic_JJ uncertainty_NN ._. Several_JJ measures_NNS were_VBD taken_VBN
        to_TO increase_VB the_DT probability_NN of_IN success_NN ._. We_PRP used_VBD robust_JJ ,_,
        model-free_JJ ,_, allele-sharing_JJ genetic_JJ analyses_NNS to_TO address_VB the_DT
        complexity_NN ,_, we_PRP studied_VBD a_DT relatively_RB genetically_RB homogenous_JJ
        population_NN ,_, and_CC we_PRP verified_VBN that_IN all_DT putative_JJ IAs_NNP were_VBD
        saccular_NN [_NN 1_CD 20_CD 41_CD 42_CD 43_CD ]_NN ._. It_PRP is_VBZ expected_VBN that_IN a_DT
        genetically_RB homogeneous_JJ population_NN ,_, particularly_RB one_CD with_IN a_DT
        recent_JJ population_NN bottleneck_NN [_NN 37_CD 38_CD ]_NN ,_, segregates_NNS for_IN
        fewer_JJR disease_NN loci_NN thereby_RB allowing_VBG a_DT smaller_JJR sample_NN size_NN
        to_TO be_VB informative_JJ ._. Additionally_RB ,_, our_PRP$ study_NN design_NN was_VBD
        cost-effective_JJ ,_, two-stage_JJ design_NN with_IN 48_CD ASPs_NNP ._. We_PRP are_VBP
        collecting_VBG an_DT additional_JJ 150_CD ASPs_NNP for_IN further_JJ study_NN ._.
        The_DT most_RBS promising_JJ locus_JJ with_IN a_DT maximum_JJ MLS_NNP of_IN 2_CD ._. 6_CD was_VBD
        on_IN chromosome_NN 19_CD ._. The_DT peak_NN is_VBZ located_VBN approximately_RB in_IN
        19_CD q_NN 12_CD -_: 13_CD ,_, a_DT gene-rich_JJ region_NN containing_VBG a_DT number_NN of_IN loci_NN
        related_VBN to_TO cerebrovascular_NN ,_, cardiovascular_JJ and_CC membrane_NN
        physiology_NN and_CC pathobiology_NN ._. These_DT include_VBP urokinase-type_JJ
        plasminogen_NN activator_NN receptor_NN (_( PLAUR_NNP ;_: MIM_NNP 173391_CD ,_, see_VBP
        Online_NNP Mendelian_NNP Inheritance_NNP in_IN Man_NN
        http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN omim_NN /_NN )_) [_NN 44_CD ]_NN ,_, apolipoproteins_NNS
        E_NNP (_( MIM_NNP 107741_CD )_) ,_, CII_NNP (_( MIM_NNP 207750_CD )_) and_CC CI_NNP (_( MIM_NNP 107710_CD )_) ,_, human_JJ
        brain-specific_JJ Na_NNP (_( +_NN )_) -_: dependent_JJ inorganic_JJ phosphate_NN
        cotransporter_NN (_( hBNPI_NN ,_, 19_CD q_NN 13_CD )_) [_NN 45_CD ]_NN ,_, cardiac_JJ troponin_NN I_PRP
        (_( TnIc_NNP ,_, 19_CD q_NN ;_: MIM_NNP 191044_CD )_) [_NN 46_CD 47_CD ]_NN ,_, cerebral_JJ autosomal_NN
        dominant_JJ arteriopathy_NN with_IN subcortical_JJ infarcts_NNS and_CC
        leukoencephalopathy_NN (_( CADASIL_NNP ,_, caused_VBN by_IN mutations_NNS in_IN the_DT
        Notch_NNP 3_CD gene_NN ,_, 19_CD q_NN 12_CD ;_: MIM_NNP 602275_CD )_) [_NN 48_CD ]_NN ,_, isolated_VBD cardiac_JJ
        conduction_NN disease_NN (_( 19_CD q_NN 13_CD ._. 3_LS ;_: MIM_NNP 113900_CD )_) [_NN 49_CD ]_NN ,_, and_CC
        progressive_JJ familial_NN heart_NN block_NN type_NN I_PRP (_( PF-HBI_NNP ,_,
        19_CD q_NN 13_CD ._. 2_LS -_: 13_CD ._. 3_LS ;_: MIM_NNP 113900_CD )_) [_NN 50_CD ]_NN ._. Mutations_NNP in_IN the_DT
        P_NN /_NN Q-_NNP type_NN Ca_MD (_( 2_CD +_NN )_) -_: channel_NN alpha_NN 1_CD A-_NNP subunit_NN gene_NN on_IN 19_CD q_NN 12_CD
        cause_VB familial_NN hemiplegic_JJ migraine_NN ,_, episodic_JJ ataxia_NN type_NN 2_CD ,_,
        and_CC spinocerebellar_NN ataxia_NN type_NN 6_CD (_( MIM_NNP 141500_CD )_) [_NN 51_CD 52_CD ]_NN
        ._.
        It_PRP is_VBZ noteworthy_JJ that_DT none_NN of_IN the_DT regions_NNS in_IN which_WDT we_PRP
        found_VBD some_DT evidence_NN for_IN linkage_NN ,_, either_CC tentative_JJ or_CC
        suggestive_JJ ,_, are_VBP similar_JJ to_TO the_DT regions_NNS detected_VBD in_IN another_DT
        recent_JJ genome-wide_JJ scan_VB for_IN IA_NNP susceptibility_NN genes_NNS [_NN 53_CD ]_NN
        ._. Although_IN our_PRP$ study_NN found_VBD evidence_NN for_IN a_DT region_NN with_IN
        tentative_JJ linkage_NN on_IN chromosome_NN 7_CD q_NN ,_, the_DT region_NN identified_VBN
        in_IN this_DT study_NN is_VBZ near_IN the_DT telomere_NN and_CC does_VBZ not_RB overlap_VB
        with_IN the_DT region_NN of_IN suggestive_JJ linkage_NN near_IN the_DT centromere_NN
        on_IN 7_CD q_NN identified_VBN in_IN Onda_NNP et_CC al_NN ._. [_NN 53_CD ]_NN ._. The_DT populations_NNS
        that_WDT were_VBD studied_VBN are_VBP distinct_JJ ,_, Finns_NNP as_IN compared_VBN to_TO
        Japanese_JJ ;_: however_RB ,_, both_DT samples_NNS were_VBD small_JJ and_CC it_PRP is_VBZ
        therefore_RB possible_JJ that_IN there_EX may_MD yet_RB be_VB some_DT overlap_VB in_IN
        genetic_JJ predisposition_NN ._.
      
      
        Conclusions_NNP
        We_PRP detected_VBD two_CD regions_NNS of_IN suggestive_JJ linkage_NN ,_, one_CD on_IN
        chromosome_NN 19_CD and_CC the_DT other_JJ on_IN the_DT X_NNP chromosome_NN in_IN a_DT sample_NN
        of_IN Finnish_JJ ASPs_NNP ._. Although_IN we_PRP initially_RB detected_VBD regions_NNS of_IN
        tentative_JJ linkage_NN on_IN chromosomes_NNS 4_CD ,_, 6_CD ,_, 7_CD p_NN ,_, 7_CD q_NN and_CC 14_CD ,_, the_DT
        regions_NNS on_IN 7_CD p_NN and_CC 14_CD were_VBD excluded_VBN upon_IN additional_JJ
        genotyping_VBG ._. None_NN of_IN the_DT regions_NNS detected_VBD in_IN this_DT study_NN
        overlap_VB with_IN the_DT regions_NNS detected_VBD in_IN a_DT sample_NN of_IN Japanese_NNP
        ASPs_NNP [_NN 53_CD ]_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD (_( JMO_NNP )_) participated_VBD in_IN the_DT study_NN design_NN and_CC
        directed_VBD the_DT statistical_JJ genetic_JJ analyses_NNS and_CC provided_VBN
        substantial_JJ input_NN to_TO the_DT manuscript_NN ._. Author_NN 2_CD (_( SV_NNP )_)
        performed_VBN most_JJS of_IN the_DT higher_JJR resolution_NN genotyping_VBG ._. Author_NN
        3_CD (_( HK_NNP )_) participated_VBD in_IN the_DT study_NN design_NN and_CC implementation_NN ,_,
        participated_VBD in_IN DNA_NNP isolation_NN and_CC performed_VBN most_JJS of_IN the_DT
        primer-extension_JJ pre-amplification_JJ reactions_NNS ._. Author_NN 4_CD (_( AR_NNP )_)
        participated_VBD in_IN the_DT design_NN of_IN the_DT family_NN collection_NN ,_, and_CC
        contacted_VBD and_CC collected_VBD the_DT family_NN information_NN ._. Author_NN 5_CD
        (_( JH_NNP )_) conceived_VBD of_IN the_DT family_NN data_NN collection_NN and_CC supervised_JJ
        AR_NNP ._. Author_NN 6_CD (_( MR_NNP )_) coordinated_VBN the_DT collection_NN of_IN blood_NN
        specimens_NNS ._. Author_NN 7_CD (_( L-LK_NNP )_) performed_VBD the_DT statistical_JJ
        analyses_NNS under_IN the_DT supervision_NN of_IN JMO_NNP ._. Author_NN 8_CD (_( GT_NNP )_)
        participated_VBD in_IN the_DT study_NN design_NN and_CC coordination_NN ,_, DNA_NNP
        isolation_NN ,_, genotyping_VBG ,_, drafting_VBG the_DT manuscript_NN ,_, and_CC
        obtained_VBD funding_NN for_IN the_DT study_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
